Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Plerixafor · Mozobil

Small molecule · Antagonist of CXCR4 chemokine receptor (CXCR4) · developed by Genzyme

Approved FDA, Dec 2008
SNY Developer
1 Registered trials

What is Plerixafor?

Plerixafor is a small-molecule inhibitor of the CXCR4 chemokine receptor that blocks binding of its ligand SDF-1α, which otherwise anchors hematopoietic stem cells in the bone marrow. By disrupting this interaction, it mobilizes hematopoietic stem cells into the peripheral blood, and it is studied in diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mozobil
Drug type
Small molecule
Targets
CXCR4 chemokine receptor (CXCR4)
Mechanism
Antagonist of CXCR4 chemokine receptor (CXCR4)
Pathways
SDF-1α/CXCR4 signaling, hematopoietic stem cell trafficking and homing
Therapy area
Oncology
Developer
Genzyme (SNY)
FDA status
Approved as Mozobil (December 15, 2008), NDA022311 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 19, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02570542 Phase 2 Diffuse Large B-cell Lymphoma (DLBCL) Active not recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

Other drugs acting on CXCR4

More from Genzyme

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Plerixafor

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.